Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR013227)
Formula Reactant SN-38 Product 10-O-glucuronyl-SN-38
Reactant Info Product Info
Metabolic Enzyme UDP-glucuronosyltransferase 1A1 (UGT1A1) DME Info
UDP-glucuronosyltransferase 1A9 (UGT1A9) DME Info
Metabolic Type Conjugation - O-gluccuronidation
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR007484 SN-38 SN-38G Conjugation - Glucuronidation SN-38 [1], [2]
MR001227 SN-38 Glucuronidated Sn-38 Conjugation - Glucuronidation Irinotecan hydrochloride [3], [4], [5]
MR013627 SN-38 SN-38 G Unclear T-0128 [6]
MR012145 SN-38 SN-38 glucuronide Unclear - Unclear Etirinotecan pegol [7]
References
1 Clinical pharmacokinetics and metabolism of irinotecan (CPT-11)
2 Individualization of Irinotecan Treatment: A Review of Pharmacokinetics, Pharmacodynamics, and Pharmacogenetics
3 Pharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C]CPT-11 in cancer patients Drug Metab Dispos. 2000 Apr;28(4):423-33.
4 Transporter and metabolic enzyme-mediated intra-enteric circulation of SN-38, an active metabolite of irinotecan: A new concept. Biochem Biophys Res Commun. 2023 Jul 12;665:19-25. doi: 10.1016/j.bbrc.2023.04.109.
5 Opioid-induced microbial dysbiosis disrupts irinotecan (CPT-11) metabolism and increases gastrointestinal toxicity in a murine model. Br J Pharmacol. 2023 May;180(10):1362-1378. doi: 10.1111/bph.16020.
6 Clinical and pharmacologic study of the novel prodrug delimotecan (MEN 4901/T-0128) in patients with solid tumors
7 Integrated population pharmacokinetics of etirinotecan pegol and its four metabolites in cancer patients with solid tumors

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.